Quantitative approach to assess function and apoptosis changes in the H9C2 cardiomyocyte cell line following differentiation and Doxorubicin exposure KU Leuven
Introduction: For some decades, the anthracycline doxorubicin (DOX) has been used in the treatment of solid tumors and leukemia. It is one of the most widely and successfully applied chemotherapeutic drugs and over the last 20 years has increased the 5-year survival rates for pediatric cancer patients from 58% to 80%. However, the clinical utility and dosage regimens of DOX are often limited by severe side effects.
The most severe side ...